RenovoRx (Nasdaq: RNXT) is a life sciences company developing novel precision oncology therapies based on a local drug delivery platform for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel and patented approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Its Phase III lead product candidate is a novel oncology drug-device combination product. It is being investigated under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. The investigational drug-device combination candidate utilizes RenovoCath®, the Company’s FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. The intra-arterial infusion of gemcitabine HCl by the RenovoCath catheter is currently being evaluated for the treatment of LAPC by the Center for Drug Evaluation and Research (the drug division of FDA).
RenovoRx is also actively exploring other commercialization strategies utilizing its TAMP technology and FDA-cleared RenovoCath delivery system as a stand-alone device. RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. The intra-arterial infusion of gemcitabine HCl by the RenovoCath catheter is currently under investigation and has not been approved for commercial sale.
Company Details
- Employees
- 24
- Address
- 2570 W El Camino Real,
- Phone
- 650-284-4433
- sh****@****orx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- renovorx.com
- Keywords
- jobs.
- HQ
- Mountain View, California
Renovorx (Nasdaq: Rnxt) Questions
Renovorx (Nasdaq: Rnxt)'s helpline number is 650-284-4433
Renovorx (Nasdaq: Rnxt)'s website is renovorx.com
Renovorx (Nasdaq: Rnxt)'s LinkedIn profile is https://www.linkedin.com/company/renovorx
Renovorx (Nasdaq: Rnxt) has
24 employees.
View email and phone details for 24
employees at Renovorx (Nasdaq: Rnxt).
Renovorx (Nasdaq: Rnxt)'s industry is
Biotechnology Research
Renovorx (Nasdaq: Rnxt)'s top competitors are
Summit Therapeutics, Inc.,
Maky Zanganeh & Associates,
Nina Capital,
Spinogenix, Inc.,
Pulse Biosciences, Inc.,
Impedimed,
Cortec,
Pharmacyclics, An Abbvie Company,
Neu Health,
Leap Therapeutics.
Renovorx (Nasdaq: Rnxt)'s support email address is shaun@renovorx.com
Renovorx (Nasdaq: Rnxt)'s categories are Biotechnology Research
